glp 1 and bulimia The rapid rise of GLP-1 receptor agonists presents a complex dilemma for clinicians managing patients with eating disorders. While these medications show potential in reducing binge eating behaviors by targeting brain reward GLP‐1 Receptor Agonist Medications for

L- 4050 40

Oral Dis (2015) 21(2):15662

She carefully evaluates each treatment she offers to ensure it meets the highest standards of safety, precision, and patient-centered care

Healthcare providers routinely manage patients on both medications, but appropriate monitoring and patient education remain essential components of safe combination therapy

Riding the wave of success from obesity drugs like WEGOVY and ZEPBOUND , which together generated USD 10.8 billion in sales and, according to DelveInsight, are forecasted to hit USD 22.5 billion by 2034, pharmaceutical companies are scrambling to expand their pipelines